Introduction
============

Rationale
---------

Pancreatic adenocarcinomas are mostly at the advanced stage when diagnosed. The prognosis is poor, with a 5-year survival rate of around 8%.[@b1-cmar-10-5965] Although systemic chemotherapy is the most important first-line treatment for locally advanced and metastatic pancreatic adenocarcinomas, there is no consensus about which chemotherapy regimen is the most effective.

Randomized controlled trials (RCTs) have compared various chemotherapy regimens, providing important direct evidence. However, the number of RCTs is limited and direct comparisons between many of the regimens are lacking.

Meta-analysis provides a method for summarizing available evidence as a supplement for individual RCTs. However, traditional pairwise meta-analysis is limited in value because it only compares two groups of treatments, and a lack of direct one-to-one comparison studies can make certain comparisons of available treatments impossible. Thus, the traditional meta-analysis method may not be suitable for analyzing and summarizing the efficacy of the several chemotherapy regimens simultaneously for pancreatic adenocarcinomas.

Network meta-analysis offers a solution to these problems, allowing direct and indirect comparisons to be combined, so that several treatments can be compared simultaneously.[@b2-cmar-10-5965]--[@b4-cmar-10-5965] When there is no available direct comparison between two therapies, network meta-analysis allows an indirect comparison. Bayesian analysis can be applied to network meta-analysis, allowing for inclusion of trials with more than two treatment arms, multiple comparisons, and more precise and stable outcomes. More importantly, Bayesian network meta-analysis can combine different measures of survival (hazard ratio \[HR\] and median survival duration) in a single analysis, avoiding the need for separate analyses for studies with different measurement methods and avoiding potential selection bias from only including studies with the same measurement methods.[@b5-cmar-10-5965]

There have been two previous network meta-analyses of systemic regimens for locally advanced and metastatic pancreatic cancer. The first only included 22 studies and compared nine regimens, and it did not compare response rates.[@b6-cmar-10-5965] A recent network meta-analysis by Liu et al compared 12 chemotherapy regimens from 20 included studies.[@b7-cmar-10-5965] The previous meta-analyses synthesized the data provided by trials comparing chemotherapy regimens, but did not provide a data summary or a ranking of the efficacy of chemotherapy regimens for locally advanced and metastatic pancreatic cancer covering all available studies published over a long interval and including multiple outcomes.

Objectives
----------

The aim of the present study, therefore, was to use a network meta-analysis to compare as comprehensively as possible the available systemic chemotherapy regimens for locally advanced and metastatic pancreatic adenocarcinoma, summarizing and ranking them in terms of overall survival, progression-free survival, response rate, and grade 3--4 hematological toxic effects, to provide some objective clues or references for future research and clinical practice. We included all the studies we could find that were published in the last 15 years; this resulted in an analysis of 63 regimens, the largest number analyzed to date.

Materials and methods
=====================

Study design
------------

The analysis was designed to rank chemotherapy regimens by overall survival, progression-free survival, response rate, and grade 3--4 hematological toxicities using Bayesian network meta-analysis.

Search strategy and selection criteria
--------------------------------------

This study was conducted in accordance with the Preferred Reporting Items for Systematic reviews and Meta-Analyses guidelines.[@b8-cmar-10-5965] We searched the PubMed, Embase, Cochrane Collaboration database, [ClinicalTrials.gov](http://ClinicalTrials.gov), and the reference lists of all relevant articles, including relevant reviews, for RCTs that compared systemic chemotherapy regimens for advanced pancreatic adenocarcinoma that included both locally advanced pancreatic adenocarcinoma and metastatic pancreatic adenocarcinoma as first treatments (or compared regimens with placebo). The search was for articles published in English between January 1, 2002, and May 2, 2017. The reasons for including RCTs published in last 15 years, the search terms, a description of the selection process, and a summary of results are shown in Supplementary S1. Relevant reports published on the US Food and Drug Administration website were searched for additional publications.

We included RCTs that compared two or more systemic chemotherapy regimens as first-line treatments for locally advanced and metastatic pancreatic adenocarcinomas, or that compared a regimen or regimens with placebo. To increase the number of trials and treatment methods that could be analyzed within the network, we also included a typical randomized clinical trial published in 1995 that compared gemcitabine and 5-fluorouracil (5-FU). This connected gemcitabine and 5-FU; otherwise, two networks would have been required. We excluded RCTs investigating metastatic pancreatic cancer only. We also excluded studies if they considered only one systemic regimen, or compared second-line treatments, or did not use randomization for allocating the treatment.

Data extraction, outcomes, and assessment for risk of bias
----------------------------------------------------------

Two investigators selected the articles, reviewed the full reports of the included studies, and independently collected information into electronic spreadsheets. Disagreements such as the basic trial information or the HR or odds ratio (OR) to be extracted from a trial were resolved by discussion between the two investigators. The process if a consensus could not be reached was for a third investigator to help resolve the discrepancy, with the authority to make the final decision. Supplementary S2 lists the data extracted from the articles. For reports of the same RCT published at different times, we gave precedence to the updated data.

The primary outcomes of the meta-analysis were overall survival and progression-free survival after the systemic treatment of locally advanced and metastatic pancreatic adenocarcinoma. For this, our preferred outcome measure was the reported HRs, because HRs provide time-to-event information and take censoring into account.[@b5-cmar-10-5965] When an article did not report HRs, we estimated them from the survival curves using the methods of Tierney et al.[@b9-cmar-10-5965] If neither HRs nor survival curves were reported, we collected information about median survival durations. The secondary outcomes were response rate and hematological toxicity; the extraction methods for these are presented in Supplementary S2.

Two investigators independently assessed the risk of bias for the included studies using the Cochrane Risk of Bias method.[@b10-cmar-10-5965] Disagreement was resolved by discussion between the two investigators or by the intervention of a third investigator to reach consensus.

Data synthesis and analysis
---------------------------

For the meta-analyses of overall survival and progression survival, we used both fixed-effects and random-effects models. A random-effects model was used because of potential heterogeneity. The results obtained with a fixed-effects model are shown in the supplement. By using the approach described by Woods et al,[@b5-cmar-10-5965] different measures (HRs and survival duration) could be combined into a single-network meta-analysis, avoiding potential selection bias. For the meta-analyses of response rate and toxic effects, we calculated and compared the ORs and 95% credible interval (CrI) using the WinBUGS model described by Chaimani.[@b11-cmar-10-5965]

We also performed a traditional pairwise random-effects meta-analysis of direct comparisons. The HRs and ORs were calculated respectively for all outcomes, each with a 95% CI, and we evaluated the heterogeneity of each pairwise comparison.[@b12-cmar-10-5965] A comparison of the direct comparison results with the pooled HRs and OR from the network meta-analysis allowed a rough assessment of any inconsistency between the direct and indirect comparisons.

To ensure study comparability, the RCT selection criteria were strictly followed and heterogeneity was evaluated. To detect clinical heterogeneity, the baseline characteristics of the RCT subjects were compared and the I[@b2-cmar-10-5965] statistics were calculated. To account for other heterogeneities that are difficult to detect, a random-effects model was used to analyze primary outcomes in the main text. Results obtained with a fixed-effects model are shown in the supplement.

To assess the convergence of the Bayesian model, we evaluated the trace plots and the Brooks--Gelman--Rubin statistic.[@b13-cmar-10-5965] We evaluated each model by comparing the number of data points and the mean posterior deviance, and compared the deviance information criterion between the fixed-effects and random-effects models. We assessed the ranking probabilities for each chemotherapy regimen for each outcome, reporting the rank as the surface under the cumulative ranking curve.[@b14-cmar-10-5965] We plotted a funnel plot for each outcome to detect any publication bias in the network meta-analysis.[@b14-cmar-10-5965]

The traditional pairwise meta-analysis was performed using Stata 13.1 (StataCorp LCC, College Station, TX, USA) with a meta fixed- and random-effects meta-analysis package (<http://www.stata-journal.com/article.html?article=sbe24_2>), and the Bayesian network meta-analysis was performed using WinBUGS version 1.4.3 (Imperial College and MRC, Cam-bridge, UK), supplemented with ITC 2.0 (Canadian Agency for Drugs and Technologies in Health, Ottawa, Canada). In the network meta-analysis, we used non-informative uniform and normal prior distributions.[@b2-cmar-10-5965],[@b3-cmar-10-5965] We compiled two Markov chains and generated two sets of initial values to fit the model. For the parameter setting, we used 5,000 burn-ins and a thinning interval of 6--25 for each chain, updating to 35,000--55,000 iterations. The detailed parameters for each outcome measure in the network meta-analysis are listed in Table S2.

Results
=======

Study selection and study characteristics
-----------------------------------------

The search of databases and other resources identified a total of 2,133 papers ([Figure 1](#f1-cmar-10-5965){ref-type="fig"}; Supplementary S1). Initial screening of the titles and abstracts resulted in the exclusion of 1,971 of these. The remaining 162 potentially eligible articles were subjected to a detailed assessment of the full text, resulting in the final inclusion of 68 publications, reporting 68 RCTs. These compared 63 systemic chemotherapy regimens or placebo ([Figure 2](#f2-cmar-10-5965){ref-type="fig"}; [Tables 1](#t1-cmar-10-5965){ref-type="table"} and [2](#t2-cmar-10-5965){ref-type="table"}; Supplementary S3). The risks of bias for the studies are shown in Supplementary S4. The most common high risk was related to the blinding of participants and personnel (performance bias).

Participants
------------

The included studies involved a total of 14,909 patients randomized to receive one of the 63 systemic chemotherapy regimens or placebo. The mean sample size was 219 participants (range 18--832), and 56.5% of the participants overall were male. The maximum and minimum median ages across all the included RCTs were 67.4 and 49.9 years, respectively. Around 72.8% of the total participants had metastatic pancreatic adenocarcinomas ([Table 1](#t1-cmar-10-5965){ref-type="table"}).

Primary outcomes
----------------

Supplementary S3 lists the included studies. The network meta-analysis for overall survival included 62 studies comparing 54 treatments that reported overall survival information (Supplementary S5). In 61 of these studies, HRs for deaths could be found directly or calculated indirectly; the remaining study reported overall survival duration. Supplementary S6 presents the detailed results of the fixed- or random-effects network meta-analysis for overall survival. The 13 top-ranked chemotherapy regimens (by surface under the cumulative ranking curve) are shown in [Figure 3](#f3-cmar-10-5965){ref-type="fig"}, which also includes gemcitabine and the lowest-ranked regimen as references. Compared with gemcitabine, the following chemotherapy regimens had a high ranking because of increased overall survival: NSC-631570 (HR vs gemcitabine monotherapy 0.44, 95% CrI 0.24--0.76), gemcitabine+NSC-631570 (HR 0.45, 0.24--0.86), PEFG (cisplatin + epirubicin + fluorouracil + gemcitabine; HR 0.63, 0.41--0.96), FLEC (fluorouracil + leucovorin + epirubicin + carboplatin; HR 0.65, 0.43--0.98), GemCape (gemcitabine + capecitabine; HR 0.82, 0.74--0.92), gemcitabine + erlotinib (HR 0.83, 0.69--0.99), and GS (gemcitabine+S-1, HR 0.84, 0.73--0.98), as shown in [Figure 3](#f3-cmar-10-5965){ref-type="fig"} and Supplementary S6. Compared with gemcitabine, placebo was the lowest ranked chemotherapy regimen for improving overall survival (HR 7.14, 2.13--25.00).

The analysis of progression-free survival included 37 studies that compared 30 treatments strategies (Supplementary S5). Compared with gemcitabine, the following chemotherapy regimens had the highest ranking, with longer progression-free survival: PEFG (HR 0.51, 0.34--0.77), gemcitabine+TH-302 (HR 0.59, 0.40--0.87), GS (HR 0.63, 0.55--0.74), gemcitabine+IMM-101 (HR 0.58, 0.38--0.92), gemcitabine+5-FU (HR 0.71, 0.57--0.88), GemCape (HR 0.77, 0.63--0.92), and GemOX (gemcitabine + oxaliplatin, HR 0.86, 0.75--0.97), as shown in [Figure 3](#f3-cmar-10-5965){ref-type="fig"} and Supplementary S7. BAY 12-9566 had the lowest efficacy ranking, with the shortest progression-free survival compared with gemcitabine (HR 1.89, 1.47--2.44).

Secondary outcomes
------------------

Information on the overall response rate was reported by 50 studies, which compared 42 chemotherapy regimens; disease control rate was reported in 44 studies comparing 43 treatment strategies (Supplementary S5). Compared with gemcitabine, the following chemotherapy regimens had the highest ranking, with increased overall response rates: PEFG (OR 7.16), gemcitabine+NSC-631570 (OR 10.36), GS (OR 3.49), gemcitabine + axitinib (OR 3.19), gemcitabine + irinotecan (OR 2.94), PG (gemcitabine + pemetrexed, OR 2.30), and GemCape (OR 2.15), as shown in [Figure 4](#f4-cmar-10-5965){ref-type="fig"} and Supplementary S8. Similarly, the following regimens had the highest improved disease control rate ranking: NSC-631570 (OR 7.10), PEFG (OR 4.27), GS (OR 2.65), and GemCis (gemcitabine + cisplatin, OR 2.20), as shown in [Figure 4](#f4-cmar-10-5965){ref-type="fig"} and Supplementary S8. BAY 12-9566 was the lowest ranked regimen for improving the overall response rate (OR 0.13) and disease control rate (HR 0.28) compared with gemcitabine.

The meta-analysis of hematological toxicity included 58 studies that reported information on grade 3--4 hema-tological toxicity, which compared 50 treatment strategies (Supplementary S5 and S9; [Figure 5](#f5-cmar-10-5965){ref-type="fig"}). Compared with gemcitabine, the following regimens were ranked the most likely to result in grade 3--4 hematological toxic effects: PG (OR 4.68), FLEC (OR 4.52), gemcitabine+TH-302 (OR 3.12), gemcitabine + exatecan (OR 2.58), GS (OR 2.40), and gemcitabine + masitinib (OR 2.41), as shown in [Figure 5](#f5-cmar-10-5965){ref-type="fig"} and Supplementary S9. Gastrazole (OR 0.03) had the lowest ranked grade 3--4 hematological toxicity compared with gemcitabine.

Ranking
-------

Supplementary S10 summarizes the ranks of the various regimens for each outcome. For overall survival, NSC-631570 and gemcitabine+NSC-631570 ranked the first and second most efficacious chemotherapy regimens, respectively, with placebo ranking the last. For progression-free survival, PEFG and BAY 12-9566 were the highest ranked. PEFG and gemcitabine+NSC-631570 were the regimens showing the first- and second-ranked overall response rates. PG and FLEC were the most toxic regimens, ranked 1 and 2 for grade 3--4 hematological toxicity.

Model assessment
----------------

As shown in [Table 1](#t1-cmar-10-5965){ref-type="table"}, no significant heterogeneity of subject baseline characteristics was detected. For most pairwise comparisons, I[@b2-cmar-10-5965] was \<50% (Supplementary S11). The Markov chains were convergent for each model. The HR and ORs of the traditional pairwise meta-analysis and the pooled results from the network meta-analysis were similar, demonstrating that there were no major inconsistencies in the direct and indirect comparisons (Supplementary S11). The global inconsistency test showed good consistency, with the mean posterior deviance approximating the number of data points for each outcome (Supplementary S12). The results indicated that these models provided a relatively good fit to the data. A comparison-adjusted funnel plot did not reveal any significant publication bias (Supplementary S13).

Three trials had not been included in any network meta-analysis[@b15-cmar-10-5965]--[@b17-cmar-10-5965] and are summarized in Supplementary S14.

Full use of the data in tables and figures
------------------------------------------

Data in the tables and figures provide a comprehensive summary, comparison, and ranking of efficacy and safety results extracted from RCTs evaluating chemotherapy regimens in the last 15 years. They can serve as a reference or provide clues for future clinical practice or research. For example, by referring to the data provided here, RCTs comparing two or more regimens of interest could be identified and the HRs or ORs of achieving various outcomes could be easily found.

The data should be interpreted with care because they provide only an objective summary of the evidence. A chemotherapy regimen ranked first in overall survival may not be the most commonly used in clinical practice. Differences between the data obtained in this analysis and those obtained in clinical practice are an important topic for future study.

Discussion
==========

Summary of evidence
-------------------

The prognosis for pancreatic cancer is poor.[@b1-cmar-10-5965] For a long time, gemcitabine monotherapy has been the standard first-line treatment for patients with locally advanced and metastatic pancreatic cancer.[@b18-cmar-10-5965] More recently, researchers have tried many new antitumor agents and chemotherapy regimens to improve survival. Our Bayesian analysis compared and ranked all the available chemotherapy regimens for locally advanced and metastatic pancreatic adenocarcinoma assessed by RCTs over the last 15 years.

Key results and interpretations
-------------------------------

Our meta-analysis found seven chemotherapy regimens that may achieve better overall survival than gemcitabine mono-therapy, with NSC-631570 and gemcitabine+NSC-631570 having the highest rank (HR \<0.5). NSC-631570 (Ukrain) is a semi-synthetic compound of the alkaloid chelidonine and thiophosphoric acid.[@b19-cmar-10-5965] The use of NSC-631570 and gemcitabine+NSC-631570 as clinical trial chemotherapy regimens for locally advanced and metastatic pancreatic cancer was reported by Gansauge et al in 2002.[@b19-cmar-10-5965] This trial included only 90 participants (30 participants per group); nevertheless, both NSC-631570 and gemcitabine+NSC-631570 resulted in better overall survival than gemcitabine, with median overall survival intervals of 5.2 months in the gem-citabine group, 7.9 months in the NSC-631570 group, and 10.4 months in the gemcitabine+NSC-631570 group. However, the following factors limited the clinic application of these two chemotherapy regimens. Side effects such as tumor bleeding could occur after treatment with NSC-631570, and cancer treatment using NSC-631570 should be performed with special medical care. Additionally, the relatively small number of participants means that a large-scale RCT is needed to confirm the superiority and safety of these regimens over gemcitabine monotherapy before they could be used in clinical treatment widely.

PEFG, FLEC, GemCape, gemcitabine + erlotinib, and GS also had a high ranking and achieved improved overall survival compared with gemcitabine, with the longest reported median survival time being 9.3,[@b20-cmar-10-5965] 7.9,[@b21-cmar-10-5965] 7.1--10.3,[@b22-cmar-10-5965]--[@b26-cmar-10-5965] 6.24--7.6,[@b27-cmar-10-5965],[@b28-cmar-10-5965] and 8.6--13.7 months,[@b29-cmar-10-5965]--[@b33-cmar-10-5965] respectively. In comparison, placebo was found to be the least effective regimen in terms of overall survival (HR 7.14), with the median survival time reported as about 4.5 months.[@b34-cmar-10-5965] This confirmed the necessity of chemotherapy for locally advanced and metastatic pancreatic cancer.

In our meta-analysis, seven chemotherapy regimens had a high ranking and could achieve improved progression-free survival compared with gemcitabine, with PEFG being the most outstanding (HR 0.51). The trial comparing PEFG and gemcitabine for locally advanced and metastatic pancreatic cancer was reported by Reni et al in 2005.[@b20-cmar-10-5965] Their RCT included 99 patients (PEFG, 52 patients; gemcitabine, 47 patients), with PEFG showing a significantly longer median progression-free survival time than gemcitabine (5.4 vs 3.3 months). Care should be taken when interpreting the progression-free survival rankings because only 38 of the 68 studies reported progression-free survival as an outcome. For example, NSC-631570 and gemcitabine+NSC-631570, which had the highest overall survival ranking, were not included in the network meta-analysis of progression-free survival.

Secondary results and interpretations
-------------------------------------

Among the seven chemotherapy regimens that had a high ranking and showed an improved overall response rate compared to gemcitabine, PEFG and gemcitabine+NSC-631570 had the highest rank (OR \>7). In the study reported by Reni et al,[@b20-cmar-10-5965] the overall response rate of PEFG was 38.5%, compared with 8.5% for gemcitabine. In the study by Gansauge et al, the overall response rate of gemcitabine+NSC-631570 was 21.4%, compared with 3.6% for gemcitabine.[@b19-cmar-10-5965] NSC-631570 ranked first and achieved the best disease control rate (OR 7.10), reaching 75.0%; in the same trial, the disease control rate of gemcitabine was 32.1%.[@b19-cmar-10-5965]

Our analysis showed that PG and FLEC ranked the most grade 3--4 hematologically toxic (OR \>4). In a comparison of PG with gemcitabine, grade 3 or 4 neutropenia was significantly more common (45.1% vs 12.8%), as were anemia (13.9% vs 2.9%) and thrombocytopenia (17.9% vs 6.2%).[@b35-cmar-10-5965] A study comparing FLEC and gemcitabine found grade 3--4 toxicities in the FLEC group of thrombocytopenia (25.3%), leukopenia (19.7%), and anemia (14%), compared with leukopenia (7.5%), anemia (2.9%), and thrombocytopenia (1.4%) in the gemcitabine group.[@b21-cmar-10-5965]

Other regimens
--------------

This analysis included only regimens in RCTs that included participants with locally advanced and metastatic pancreatic cancer. None of the RCTs included only participants with metastatic pancreatic cancer. Several chemotherapy regimens have shown great potential in recent years in the treatment of metastatic pancreatic cancer, especially FOLFIRINOX (oxaliplatin + irinotecan + fluorouracil + leucovorin) and GP (gemcitabine + nab-paclitaxel).[@b36-cmar-10-5965]--[@b38-cmar-10-5965] In the trial reported by Conroy et al,[@b36-cmar-10-5965] the use of FOLFIRINOX resulted in a median overall survival of about 11.1 months among metastatic pancreatic cancer patients (HR 0.57, 0.45--0.73 vs gemcitabine). GP was also found to result in significantly longer median overall survival than gemcitabine in metastatic pancreatic cancer patients (8.7 vs 6.6 months, HR 0.72, 0.62--0.83).[@b37-cmar-10-5965],[@b38-cmar-10-5965] These trials only included metastatic patients. The 5-year overall survival rates for locally advanced and metastatic pancreatic cancer were 11% and 3%, respectively,[@b1-cmar-10-5965] with significantly different prognoses. Nevertheless, these trials provide some indications for future study, but large-scale RCTs are needed to demonstrate the same results among all locally advanced and metastatic pancreatic cancer patients. To address the problem that some commonly used chemotherapy regimens were not included in the analysis, a similar Bayesian analysis of systemic chemotherapy for metastatic pancreatic cancer was performed. We think the combined used of these two studies would provide relatively comprehensive information for advanced pancreatic cancer.

Strengths
---------

The present study had several strengths. First, using a network meta-analysis allowed us to obtain indirect comparisons that traditional pairwise could not achieve, as well as more precise effect estimates through combining the direct and indirect comparisons.[@b2-cmar-10-5965]--[@b4-cmar-10-5965] Second, the study assessed all available RCTs and chemotherapy regimens individually and together, instead of grouping these chemotherapy regimens into several groups. Third, the study assessed the chemotherapy regimens in regard to a range of important outcomes, providing new insights into the benefit--risk ratios of the various treatments. Fourth, we combined studies with different measures into a single model, avoiding potential publication bias.[@b5-cmar-10-5965] This updated comprehensive summary of the existing evidence provides clues and reference data for use in future research and clinical practice.

Limitations
-----------

This study has some limitations. First, it only included RCTs published in the last 15 years; the reasons for this are listed in Supplementary S1. Second, there was a certain degree of heterogeneity. An attempt was made to control this heterogeneity. A random-effects model was used for the network analysis of primary outcomes in the main text. The results of a fixed-effects model are shown in Supplementary S6--S9. Third, there may be differences in the results of the network meta-analysis and those obtained in clinical practice. This is discussed in the last paragraph of the "Results" section. Some commonly used chemotherapy clinical regimens were not found in this meta-analysis. To address this limitation, a Bayesian meta-analysis of metastatic pancreatic adenocarcinoma is planned. Fourth, we decided not to perform a meta-analysis for non-hematological toxicity (the reasons are given in Supplementary S2). Fifth, we did not undertake subgroup meta-analyses or meta-regressions because most of the direct one-to-one comparisons were included only in single studies. Sixth, we were unable to construct a contribution matrix and test local inconsistency because too many direct and indirect comparisons were involved. For example, the meta-analysis of overall survival included 54 regimens, which would result in 70 direct comparisons and 1,361 indirect comparisons, leading to 100,170 variables. Most comparisons were conducted in only one study and few loops were found in the network meta-analysis; these factors make the contribution matrix and test of local inconsistency less important. Finally, our meta-analysis used published data rather than individual patient data. Despite these limitations, the comprehensive results of the study, when interpreted with some caution, can provide insights regarding the chemotherapy regimens for locally advanced and metastatic pancreatic cancer, both for future research and for clinical practice.

Conclusion
==========

Our network meta-analysis found that, of the 63 regimens considered, 7 chemotherapy regimens that may achieve better overall survival than gemcitabine monotherapy for locally advanced and metastatic pancreatic cancer patients, with NSC-631570 and gemcitabine+NSC-631570 having the highest rank. Also, seven chemotherapy regimens had a high ranking and could achieve improved progression-free survival compared with gemcitabine, with PEFG being the most outstanding. PEFG and gemcitabine+NSC-631570 ranked first in overall response and NSC-631570 ranked first in disease control. PG and FLEC had the highest grade 3--4 hematological toxicity. The results should be interpreted and applied with care; and the effectiveness and safety of some chemotherapy regimens need to be further confirmed by large-scale RCTs.

The project was funded by CAMS Initiative Fund for Medical Sciences (CIFMS) (no. 2016-I2M-1--001). We thank all patients who took part in the trials and all researchers who contributed to the trials. The meta-analysis would not have been possible without patients' and researchers' contribution.
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![Selected results of the random-effects model network meta-analyses of overall survival and progression-free survival.\
**Notes:** The treatment regimens are listed in order of overall survival and progression-free survival ranked according to the SUCRA. It lists only the top 13 chemotherapy regimens (by SUCRA), and it also includes gemcitabine and the least useful regimen as references. Comparisons should be read from left to right. The intersection of the column-defining chemotherapy regimen and the row-defining regimen shows the HRs of overall survival and progression-free survival. For overall survival, an HR below 1 favors the row-defining regimen. For progression-free survival, an HR below 1 favors the column-defining regimen. Reciprocals of corresponding HRs should be taken to get HRs for comparison in the opposing direction. An explanation of the two-letter codes is provided in [Table 2](#t2-cmar-10-5965){ref-type="table"}.\
**Abbreviations:** CrI, credible interval; HR, hazard ratio; SUCRA, surface under the cumulative ranking curve.](cmar-10-5965Fig3){#f3-cmar-10-5965}

![Selected results of network meta-analysis of overall response rate and disease control rate.\
**Notes:** The treatment regimens are listed in order of overall response rate and disease control rate ranked according to SUCRA. The figure lists only the top 13 chemotherapy regimens (by SUCRA), and it also includes gemcitabine and the least useful regimen as references. Comparisons should be read from left to right. The intersection of the column-defining chemotherapy regimen and the row-defining regimen shows the ORs of overall response rate and disease control rate. For overall response rate, an OR value below 1 favors the column-defining treatment. For disease control rate, an OR value below 1 favors the row-defining treatment. Reciprocals of corresponding ORs should be taken to get ORs for comparison in the opposing direction. An explanation of the two-letter codes is provided in [Table 2](#t2-cmar-10-5965){ref-type="table"}.\
**Abbreviations:** CrI, credible interval; OR, odds ratio; SUCRA, surface under the cumulative ranking curve.](cmar-10-5965Fig4){#f4-cmar-10-5965}

![Selected results of network meta-analysis of grade 3--4 hematological toxicity.\
**Notes:** The treatment regimens are listed in order of grade 3--4 hematological toxicity ranked according to SUCRA. The figure lists only the top 13 chemotherapy regimens (by SUCRA), and it also includes gemcitabine and the least useful regimen as references. Comparisons should be read from left to right. The intersection of the column-defining chemotherapy regimen and the row-defining regimen shows the ORs of grade 3--4 hematological toxicity. For hematological toxicity, an OR value below 1 favors the row-defining treatment. Reciprocals of corresponding ORs should be taken to get ORs for comparison in the opposing direction. For an explanation of the two-letter codes, please refer to [Table 2](#t2-cmar-10-5965){ref-type="table"}.\
**Abbreviations:** CrI, credible interval; OR, odds ratio; SUCRA, surface under the cumulative ranking curve.](cmar-10-5965Fig5){#f5-cmar-10-5965}

###### 

Randomized controlled trials included in the systematic review and network meta-analysis

  Study                                     Mean or median age   Male/female (ratio %)   Metastatic/advanced (ratio %)   Total number of participants   Comparison
  ----------------------------------------- -------------------- ----------------------- ------------------------------- ------------------------------ ----------------
  Burris et al 1997[@b18-cmar-10-5965]      61.5                 117                     74                              126                            AI vs AA
  Gansauge et al 2002[@b19-cmar-10-5965]    60.9                 58                      62                              90                             AI vs BX vs BB
  Colucci 2002[@b1-cmar-10-5965]            62.0                 73                      54                              107                            AI vs BR
  Bramhall 2002[@b2-cmar-10-5965]           62.0                 71                      61                              239                            AZ vs AI
  Maisey 2002[@b3-cmar-10-5965]             61.5                 60                      65                              209                            AA vs AE
  Berlin 2002[@b4-cmar-10-5965]             65.1                 90                      90                              322                            AI vs BQ
  Ducreux 2002[@b5-cmar-10-5965]            60.0                 55                      87                              207                            AA vs CB
  Smith 2003[@b6-cmar-10-5965]              60.3                 62                      76                              55                             CE vs AI
  Moore 2003[@b7-cmar-10-5965]              66.0                 75                      63                              277                            AB vs AI
  Ducreux 2004[@b8-cmar-10-5965]            57.0                 50                      91                              63                             BY vs BZ vs AA
  Van Cutsem 2004[@b9-cmar-10-5965]         62.0                 75                      77                              688                            BI vs AI
  Rocha Lima 2004[@b10-cmar-10-5965]        61.7                 73                      81                              360                            AW vs AI
  Cantore 2004[@b11-cmar-10-5965]           62.5                 50                      51                              138                            AI vs AC
  Chen 2006[@b12-cmar-10-5965]              61.2                 53                      69                              26                             BW vs AI
  Louvet 2005[@b13-cmar-10-5965]            60.7                 77                      69                              313                            AI vs BO
  Reni et al 2005[@b20-cmar-10-5965]        60.6                 106                     71                              99                             CA vs AI
  Di Costanzo 2005[@b14-cmar-10-5965]       63.0                 82                      70                              91                             AI vs BQ
  Oettle et al 2005[@b35-cmar-10-5965]      63.0                 76                      91                              565                            BP vs AI
  Negi et al 2006[@b34-cmar-10-5965]        49.9                 31                      46                              46                             AD vs CC
  Lutz et al 2006[@b15-cmar-10-5965]        58.0                 78                      83                              96                             CF vs CI
  Chau 2006 Trial 1[@b15-cmar-10-5965]      62.0                 39                      33                              18                             AH vs CC
  Chau 2006 Trial 2[@b15-cmar-10-5965]      64.9                 86                      62                              95                             AH vs AA
  Richards 2006[@b16-cmar-10-5965]          63.5                 67                      83                              174                            AM vs AI
  Stathopoulos 2006[@b17-cmar-10-5965]      64.0                 61                      82                              130                            AW vs AI
  Heinemann 2006[@b18-cmar-10-5965]         65.0                 57                      77                              190                            BR vs AI
  Abou-Alfa 2006[@b19-cmar-10-5965]         62.7                 82                      79                              349                            AS vs AI
  Friess 2006[@b20-cmar-10-5965]            67.0                 102                     80                              89                             AN vs AI
  Moore et al 2007[@b28-cmar-10-5965]       63.9                 110                     76                              569                            AQ vs AI
  Herrmann et al 2007[@b22-cmar-10-5965]    NA                   87                      65                              319                            BM vs AI
  Boeck 2008[@b21-cmar-10-5965]             62.7                 57                      54                              188                            AG vs BM vs BO
  Cascinu 2008[@b22-cmar-10-5965]           64.0                 65                      73                              84                             BT vs BR
  Wiedenmann 2008[@b23-cmar-10-5965]        64.1                 69                      85                              59                             AI vs AV
  Spano 2008[@b24-cmar-10-5965]             63.7                 102                     57                              103                            AJ vs AI
  Eckhardt 2009[@b25-cmar-10-5965]          61.5                 160                     72                              244                            BI vs AI
  Poplin 2009[@b26-cmar-10-5965]            63.5                 96                      90                              547                            AI vs BO
  Saif 2009[@b27-cmar-10-5965]              62.0                 68                      90                              133                            AY vs AI
  Richards 2011[@b28-cmar-10-5965]          66.9                 67                      89                              130                            AP vs AI
  Cunningham 2009[@b29-cmar-10-5965]        62.0                 70                      71                              533                            AI vs BM
  Meyer 2010[@b30-cmar-10-5965]             60.3                 75                      81                              21                             AI vs BL
  Colucci 2010[@b31-cmar-10-5965]           63.0                 68                      84                              400                            AI vs BR
  Kindler 2010[@b32-cmar-10-5965]           64.3                 84                      85                              602                            AK vs AI
  Philip 2010[@b33-cmar-10-5965]            64.0                 91                      79                              743                            AI vs AL
  Kindler 2011[@b34-cmar-10-5965]           61.5                 66                      72                              630                            AJ vs AI
  Reni 2012[@b35-cmar-10-5965]              60.0                 67                      66                              105                            CG vs CH
  Ko et al 2012[@b17-cmar-10-5965]          63.8                 81                      77                              61                             CK vs CJ
  Heinrich 2011[@b36-cmar-10-5965]          61.0                 64                      75                              151                            BD vs AI
  Löhr 2012[@b37-cmar-10-5965]              61.0                 54                      76                              109                            AI vs BS
  Maraveyas 2012[@b38-cmar-10-5965]         63.0                 71                      54                              123                            AI vs BK
  Gilliam 2012[@b39-cmar-10-5965]           62.0                 105                     79                              154                            AF vs CC
  Ozaka 2012[@b40-cmar-10-5965]             64.0                 67                      72                              116                            AI vs BV
  Nakai et al 2012[@b30-cmar-10-5965]       65.0                 41                      74                              106                            AI vs BV
  Gonçalves 2012[@b41-cmar-10-5965]         62.5                 68                      80                              104                            AI vs BF
  Meng 2012[@b42-cmar-10-5965]              60.9                 65                      76                              76                             AT vs AI
  Ueno et al 2013[@b32-cmar-10-5965]        65.0                 67                      76                              832                            AI vs CD vs BV
  Okusaka et al 2017[@b33-cmar-10-5965]                                                                                                                 
  Hong 2014[@b43-cmar-10-5965]              58.0                 65                      88                              114                            BE vs AI
  Cascinu 2014[@b44-cmar-10-5965]           66.5                 73                      67                              114                            BU vs BR
  Sudo et al 2014[@b31-cmar-10-5965]        66.5                 66                      63                              101                            BV vs AI
  Middleton et al 2014[@b25-cmar-10-5965]   62.5                 76                      69                              712                            BM vs BN
  Bergmann 2015[@b45-cmar-10-5965]          63.3                 86                      72                              106                            AI vs BG
  Borad 2015[@b46-cmar-10-5965]             66.0                 74                      76                              143                            AI vs BH
  Bendell 2015[@b47-cmar-10-5965]           65.3                 100                     82                              22                             BC vs AI
  Deplanque 2015[@b48-cmar-10-5965]         62.1                 85                      84                              353                            BA vs AI
  Yamaue 2015[@b49-cmar-10-5965]            64.0                 65                      73                              153                            AO vs AI
  Kordes 2015[@b50-cmar-10-5965]            64.5                 98                      74                              121                            AQ vs AR
  Dalgleish 2016[@b51-cmar-10-5965]         67.4                 86                      84                              110                            AU vs AI
  Lee et al 2017[@b26-cmar-10-5965]         54.0                 78                      72                              214                            AI vs BM
  Laquente 2017[@b52-cmar-10-5965]          64.3                 60                      77                              99                             AX vs AI
  Middleton 2017[@b53-cmar-10-5965]         67.0                 141                     71                              142                            BJ vs AI

**Notes:** An explanation of the two-letter codes is provided in [Table 2](#t2-cmar-10-5965){ref-type="table"}.

**Abbreviation:** NA, not available.

###### 

The chemotherapy regimens included in the study with the codes used in the figures

  Code   Chemotherapy regimen                                          Code   Chemotherapy regimen                                 Code   Chemotherapy regimen
  ------ ------------------------------------------------------------- ------ ---------------------------------------------------- ------ ------------------------------------------------------------
  AA     5-FU                                                          AV     Gemcitabine + infliximab                             BQ     Gemcitabine+5-FU
  AB     BAY 12-9566                                                   AW     Gemcitabine + irinotecan                             BR     GemCis (gemcitabine + cisplatin)
  AC     FLEC (fluorouracil + leucovorin + epirubicin + carboplatin)   AX     Gemcitabine+LY2603618                                BS     Gemcitabine+ET (cationic liposomal paclitaxel)
  AD     Flutamide                                                     AY     Gemcitabine+LY293111                                 BT     Gemcitabine+CDDP (cisplatin) + cetuximab
  AE     5-FU+MMC (mitomycin)                                          AZ     Gemcitabine + marimastat                             BU     Gemcitabine+CDDP (cisplatin) + sorfenib
  AF     G17DT                                                         BA     Gemcitabine + masitinib                              BV     GS (gemcitabine+S-1)
  AG     CapOx (capecitabine + oxaliplatin)                            BB     Gemcitabine+NSC-631570                               BW     Imatinib
  AH     Gastrazole                                                    BC     Gemcitabine + olaparib                               BX     NSC-631570
  AI     Gemcitabine                                                   BD     Gemcitabine+RP101                                    BY     OXA (oxaliplatin)
  AJ     Gemcitabine + axitinib                                        BE     Gemcitabine + simvastatin                            BZ     OXFU (5-FU+oxaliplatin)
  AK     Gemcitabine + bevacizumab                                     BF     Gemcitabine + sorafenib                              CA     PEFG (cisplatin + epirubicin + fluorouracil + gemcitabine)
  AL     Gemcitabine + cetuximab                                       BG     SUNGEM (gemcitabine + sunitinib)                     CB     PF (5-FU+cisplatin)
  AM     Gemcitabine+CI-994                                            BH     Gemcitabine+TH-302                                   CC     Placebo
  AN     Gemcitabine + cilengitide                                     BI     Gemcitabine + tipifarnib                             CD     S-1
  AO     Gemcitabine + elpamotide                                      BJ     Gemcitabine + vandetanib                             CE     ZD9331
  AP     Gemcitabine + enzastaurin                                     BK     GEMWAD (gemcitabine + weight- adjusted dalteparin)   CF     Gemcitabine + docetaxel
  AQ     Gemcitabine + erlotinib                                       BL     Gemcitabine+Z-360                                    CG     PDXG (cisplatin + docetaxel + capecitabine + gemcitabine)
  AR     Gemcitabine + erlotinib + metformin                           BM     GemCape (gemcitabine + capecitabine)                 CH     PEXG (cisplatin + epirubicin + capecitabine + gemcitabine)
  AS     Gemcitabine + exatecan                                        BN     GemCape (gemcitabine + capecitabine)+GV1001+GM-CSF   CI     CDDP (cisplatin) + docetaxel
  AT     Gemcitabine + huachansu                                       BO     GemOX (gemcitabine + oxaliplatin)                    CJ     Bevacizumab + cetuximab
  AU     Gemcitabine+IMM-101                                           BP     PG (gemcitabine + pemetrexed)                        CK     Gemcitabine + bevacizumab + cetuximab

**Abbreviations:** 5-FU, 5-fluorouacil; CDDP, cisplatin; ET, cationic liposomal paclitaxel; GM-CSF, granulocyte-macrophage colony stimulating factor; MMC, mitomycin.
